Altres línies
- Nombre de publicacions
- 588
Publicacions
-
Pifarre, M; Carrera, A; Vilaplana, J; Cuadrado, J; Solsona, S; Abella, F; Solsona, F; Alves, R
TControl: A mobile app to follow up tobacco-quitting patients
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 142 81-89. .
-
Domingo, P; Sancho, F
Neisseria meningitidis and purpura fulminans in a woman with chronic liver disease
LANCET INFECTIOUS DISEASES 17 459-459. .
-
Senent, L.; Lorenzo, I.; Vicente, A.; Alonso, E.; Sanzo, C.; Ramos, F.; Arenillas, L.; Orero, M.; Navarro, B.; Marco, V.; Diez Campelo, M.; Jerez, A.; Montoro, J.; Arrizabalaga, B.; Bonanad, S.; Lluch, R.; Paz, R. D.; Font, P.; Gomis, F.; Sanz, G.
PROGNOSTIC IMPLICATION OF THE PERCENTAGE OF ERYTHROID CELLS IN BONE MARROWAT DIAGNOSIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
LEUKEMIA RESEARCH 55 151-152. .
-
Huerva, V; Traveset, AE; Vilardell, F
Topical Interferon Alpha-2b for Diffuse Conjunctival Primary Acquired Melanosis with Atypia
Ocular Immunology And Inflammation 25 284-286. .
-
Cabezon, M.; Bargay, J.; Xicoy, B.; Garcia, O.; Tormo, M.; Palomo, L.; Marce, S.; Valcarcel, D.; Pedro, C.; Jimenez, M. J.; Borras, J.; Guardia, R.; Brunet, S.; Marti, J. M.; Garcia, A.; Zamora, L.
TP53 MUTATIONS IN HIGH RISK MYELODYSPLASTIC SYNDROMES PATIENTS TREATED WITH AZACITIDINE ACCORDING TO CETLAM GROUP PROTOCOL
LEUKEMIA RESEARCH 55 155-155. .
-
Gasol Cudos, A.; Morales Murillo, S.; Panades Siurana, M. J.; Vilardell Villellas, F.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.; Salud Salvia, A.
Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution
BREAST 32 92-93. .
-
Arroyo D; Betriu A; Valls J; Gorriz JL; Pallares V; Abajo M; Gracia M; Valdivielso JM; Fernandez E
Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study
NEPHROLOGY DIALYSIS TRANSPLANTATION 32 513-520. .
-
Negredo, E; Estrada, V; Domingo, P; Gutierrez, MD; Mateo, GM; Puig, J; Bonjoch, A; Ornelas, A; Echeverria, P; Estany, C; Toro, J; Clotet, B
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 72 844-849. .
-
Saumoy, M; Tiraboschi, JM; Ordoñez-Llanos J; Ribera, E; Domingo, P; Mallolas, J; Curto, J; Gatell, JM; Podzamczer, D
Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy
HIV CLINICAL TRIALS 18 49-53. .
-
Carlos Yebenes, Juan; Carlos Ruiz-Rodriguez, Juan; Ferrer, R; Cleries, M; Bosch, A; Lorencio, C; Rodriguez, A; Nuvials, X; Martin-Loeches, I; Artigas, A; SOCMIC Catalonian Critical Care
Epidemiology of sepsis in Catalonia: analysis of incidence and outcomes in a European setting
Annals of Intensive Care 7 19-19. .
-
Rivero, A; Perez-Molina, JA; Blasco, AJ; Arribas, JR; Crespo, M; Domingo, P; Estrada, V; Iribarren, JA; Knobel, H; Lazaro, P; Lopez-Aldeguer, J; Lozano, F; Moreno, S; Palacios, R; Pineda, JA; Pulido, F; Rubio, R; de la Torre, J; Tuset, M; Gatell, JM
Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA 35 88-99. .
-
Cabre, R; Naudi, A; Dominguez-Gonzalez, M; Ayala, V; Jove, M; Mota-Martorell, N; Piñol-Ripoll G; Gil-Villar, MP; Rue, M; Portero-Otin, M; Ferrer, I; Pamplona, R
Sixty years old is the breakpoint of human frontal cortex aging
FREE RADICAL BIOLOGY AND MEDICINE 103 14-22. .
